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Sir,
Phosphatase, homologue to tensin (PTEN), is a tumour suppressor
protein that regulates the PI3K/AKT signalling pathway. Loss of
PTEN expression results in overactivation of the Akt pathway and
confers resistance to inhibitors of the epidermal growth factor
receptor (EGFR). Recently, four clinical studies have evaluated the
association between PTEN expression status and response to the
treatment of EGFR-targeted monoclonal antibodies (cetuximab and
panitumumab) in patients with metastatic colorectal cancer (mCRC)
(Frattini et al, 2007; Loupakis et al, 2009; Molinari et al, 2009;
Sartore-Bianchi et al, 2009). However, results are still inconclusive
partially because of the relatively small sample size, and the
retrospective and not controlled nature of these studies.
To derive a more precise estimation of the relationship, we
performed this meta-analysis. The sample sizes in the four studies
ranged from 12 to 85. In total, PTEN immunohistochemical
analysis was performed successfully on 231 primary tumours. Loss
of PTEN expression was detected in 87 (38%) primary tumours.
Among 231 patients analysed, 205 patients were assessable for
tumour response. The objective response rate (ORR) of mCRC
patients with loss of PTEN expression was 6% (5 of 81), whereas
the ORR of mCRC patients with normal PTEN expression was 32%
(40 of 124). Loss of PTEN expression had a negative effect on
tumour response to anti-EGFR monoclonal antibodies (pooled risk
ratio, 0.22; 95% confidence interval, 0.10–0.50; Po0.001), with no
heterogeneity between studies (P¼0.22) (Table 1). No publication
bias was found by Egger’s test (t¼1.44; P¼0.45).
In conclusion, this meta-analysis suggests that loss of PTEN
expression is associated with clinical resistance to EGFR-targeted
monoclonal antibodies in patients with mCRC. However, the
number of studies and the number of subjects included in the
meta-analysis are relatively small. Large prospective studies using
standardised unbiased methods are needed to confirm our results.
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Table 1 Tumour response to EGFR-targeted monoclonal antibodies
according to PTEN expression status
ORR (%)
Author (year)
Tumours
evaluated
PTEN
loss
PTEN
loss
PTEN
normal
Pooled RR
(95% CI) Ph
Frattini et al (2007) 27 11 0/11 (0) 10/16 (63) 0.22(0.10-0.50) 0.22
Loupakis et al (2009) 85 36 4/36 (11) 11/49 (22)
Molinari et al (2009) 38 8 0/2 (0) 2/10 (20)
Sartore-Bianchi et al
(2009)
81 32 1/32 (3) 17/49 (35)
Abbreviations: CI¼confidence interval; ORR¼objective response rate; Ph¼P value
of Q test for heterogeneity test; PTEN¼phosphatase, homologue to tensin;
RR¼risk ratio.
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